查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1976643

人工泪液市场：2026年至2032年全球预测（依产品类型、活性成分、应用、通路和年龄组别划分）

Artificial Tears Market by Product Type, Active Ingredient, Application, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人工泪液市场价值将达到 29.9 亿美元，到 2026 年将成长至 32.1 亿美元，到 2032 年将达到 49 亿美元，复合年增长率为 7.27%。

主要市场统计数据
基准年 2025 29.9亿美元
预计年份：2026年 32.1亿美元
预测年份 2032 49亿美元
复合年增长率 (%) 7.27%

人工泪液市场策略概览：清楚阐述临床需求驱动因素、配方多样性、成分选择和不断发展的通路

本报告清楚阐述了人工泪液市场变化的背景，以及这些变化对生产商、临床医生、付款者和经销商的重要性。人口结构变化、电子设备使用量的增加、隐形眼镜佩戴率的上升以及前节手术数量的增加，都推动了对缓解症状的眼科润滑剂和治疗製剂的需求增长。这些临床和行为因素，加上患者对耐受性、疗效和便利性的期望不断提高，正在推动从传统滴眼液和眼膏到凝胶和喷雾等各种产品的开发。

识别正在重新定义人工泪液市场的变革性转变，包括成分创新、包装演变、数位管道扩张和监管压力。

由于技术、法规和消费趋势的融合，该行业正经历着变革时期。成分创新正在加速，製造商优先考虑透明质酸的各种变体和分子量设计，以优化其保留效果和缓解症状。同时，向无防腐剂配方的转变正在重塑配方策略和生产要求，而无菌填充技术和高剂量无防腐剂技术的进步则开闢了新的商业性机会。

本报告严格评估了美国在 2025 年征收关税的累积影响，检视了供应链、筹资策略、价格压力和製造商的应对措施。

2025年美国征收的关税对采购、製造和分销管道的经济效益产生了累积影响。对某些进口活性成分、高剂量系统中使用的特殊聚合物以及包装组件征收更高的关税，加剧了依赖全球供应链的製造商的成本压力。因此，采购部门加快了双重采购策略，并寻求与区域供应商建立更紧密的伙伴关係，以降低贸易波动带来的风险。对于高分子量透明质酸和用于无防腐剂配方系统的特殊塑胶等原料，关税加大了上游整合和签订长期供应合约的奖励。

透过详细的細項分析，了解影响策略的产品类型、活性成分偏好、分销管道、应用案例和容量形式。

产品细分为将临床需求和商业性机会转化为具体的产品和通路策略提供了一个切实可行的观点。产品类型细分涵盖眼药水、凝胶、软膏和喷雾剂，其中滴眼液进一步细分为乳剂、溶液和悬浮液；凝胶细分为低渗透压和等渗；软膏细分为羊毛脂基和凡士林基配方；喷雾剂细分为喷雾和溶液喷雾。这种细分至关重要，因为每种细分类型都有其自身的配方挑战、储存要求和患者偏好，因此需要考虑不同的生产和监管因素。

区域分析全面考察了美洲、欧洲、中东和非洲以及亚太地区的需求因素、监管环境、製造地和分销管道采用趋势。

区域趋势导致商业性和营运需求有显着差异。在美洲，患者就医便利性、直接面向消费者的行销以及强大的线上管道应用，与强调产品安全性和标籤清晰度的法规环境并存。面向美洲市场的製造商往往优先考虑快速交货和全通路库存策略，该地区仍然是无防腐剂产品和支持长期用药的订阅模式实现差异化的关键目标市场。

企业洞察老牌製造商、敏捷专家、契约製造製造商和新参与企业如何重组其产品组合、伙伴关係和商业化方法。

人工泪液市场的企业行为体现了策略多样性：大型成熟製造商注重规模、合规应对力和广泛的分销网络，而专业公司和新参与企业则专注于细分市场差异化，例如无防腐剂技术和分子量优化的透明质酸。契约製造和合约研发组织正成为日益重要的合作伙伴，能够快速扩大新配方的生产规模，并灵活应对因关税变化而导致的采购变化。

为产业领导者提供可操作且优先考虑的建议，以加速成长、降低关税风险、优化分销，并透过创新增强差异化。

产业领导者必须优先考虑能够平衡短期韧性和长期差异化的实际措施。首先，应实现关键原材料和包装材料筹资策略的多元化，以降低关税风险和供应中断的影响，并在监管和成本权衡有利的情况下，探索区域製造伙伴关係和近岸外包。其次，应加快对无防腐剂输送系统和详细临床试验项目的投资，以检验高分子量和低分子量透明质酸的功效，因为临床差异化在专业人士和消费者的选择中正变得越来越重要。

透明的调查方法为结论提供了支持：详细揭露资料来源、专家咨询、产品映射、供应链分析和检验方法。

本研究途径结合了系统性的二手资料分析、有针对性的原始研究以及严格的检验。二级资讯来源包括同行评审的临床文献、监管指南和公开文件、专利状态、供应商能力报告以及匿名化的管道绩效指标。利用这些资讯来源，建构了产品子类型、成分路径、包装规格和分销机制的全面图谱。原始研究包括对製造商和经销商进行结构化访谈，访谈对象包括眼科医师、医院药剂师、製药工程师、包装工程师和商业负责人，旨在识别实际限制因素和新兴策略。

简明扼要地总结了对相关人员的策略意义，重点在于韧性、以病人为中心的产品设计和营运优先顺序。

人工泪液市场正处于变革的关键时期，临床需求、包装创新、数位化通路和贸易政策相互作用，共同重塑竞争格局。将配方科学（尤其是透明质酸分子变体和无防腐剂技术）与切实可行的供应链策略相结合的相关人员，将更有利于满足临床医生的偏好和患者的便利需求。同时，深入了解从医院药房到品牌电商等各个分销管道的特点，对于将产品差异化转化为可持续的市场接受度至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：人工泪液市场：依产品类型划分

  • 眼药水
  • 凝胶
  • 软膏
  • 喷

第九章：人工泪液市场（依活性成分划分）

  • 羧甲基纤维素
  • 玻尿酸
  • 聚乙二醇（PEG）
  • 聚乙烯醇

第十章：人工泪液市场：依应用领域划分

  • 过敏性结膜炎
  • 术后支持
  • 干眼症

第十一章：人工泪液市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：人工泪液市场：依年龄组别划分

  • 成人
  • 儿童

第十三章：人工泪液市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：人工泪液市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：人工泪液市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国人工泪液市场

第十七章：中国人工泪液市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alcon Inc.
  • AbbVie Inc.
  • Bausch+Lomb Corporation
  • Abbott Laboratories
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • AFT Pharmaceuticals Limited
  • Aldeyra Therapeutics, Inc.
  • CooperVision, Inc.
  • Eyenovia, Inc.
  • Hilco Vision LLC
  • I-MED Pharma Inc.
  • Lupin Limited
  • Menicon Co., Ltd.
  • Nicox SA
  • Ocular Therapeutix, Inc.
  • Similasan Corporation
  • Sun Pharmaceutical Industries Limited
  • Thea Pharma, Inc.
  • URSAPHARM Arzneimittel GmbH
  • Velocity Pharma LLC
  • Wuhan Yuanda Pharmaceutical Group Co., Ltd.
  • Zhongshan Wanhan Pharmaceutical Co., Ltd.
Product Code: MRR-69324464D1AA

The Artificial Tears Market was valued at USD 2.99 billion in 2025 and is projected to grow to USD 3.21 billion in 2026, with a CAGR of 7.27%, reaching USD 4.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.99 billion
Estimated Year [2026] USD 3.21 billion
Forecast Year [2032] USD 4.90 billion
CAGR (%) 7.27%

A strategic introduction to the artificial tears landscape framing clinical demand drivers, formulation diversity, ingredient choices, and evolving distribution pathways

This report opens with a clear framing of what is changing in the artificial tears landscape and why those changes matter to manufacturers, clinicians, payers, and distributors. Demographic shifts, increased digital device exposure, expanded contact lens wear, and higher volumes of anterior segment procedures have all elevated demand for symptomatic ocular lubricants and therapeutic formulations. These clinical and behavioral drivers intersect with heightened patient expectations for tolerability, efficacy, and convenience, prompting product development that spans traditional drops and ointments through to gels and sprays.

Product diversity is more complex than it once was. Market offerings now include drops manufactured as emulsions, solutions, or suspensions; gels differentiated as hypotonic or isotonic; ointments formulated as lanolin-based or petrolatum-based; and sprays delivered as mists or solution sprays. Ingredient strategies layer onto that complexity, with choices between carboxymethylcellulose, hyaluronic acid in high or low molecular weight forms, and preservative-free versus preserved formats that use agents such as benzalkonium chloride, polyquaternium 1, or sodium chlorite. Distribution and dispensing pathways vary from hospital pharmacy to online storefronts and traditional retail, and volume formats span multi-dose containers across several milliliter bands and unit-dose offerings in 0.5 and 1 ml sizes. Together, these dynamics set the stage for an industry that must balance clinical performance, patient convenience, regulatory compliance, and commercial agility.

Identification of transformative shifts redefining artificial tears including ingredient innovation, packaging evolution, digital channel expansion, and regulatory pressures

The industry is undergoing transformative shifts driven by converging technological, regulatory, and consumer trends. Ingredient innovation has accelerated, with manufacturers prioritizing hyaluronic acid variants and molecular-weight engineering to optimize retention and symptom relief. At the same time, the shift toward preservative-free formats is reshaping formulation strategy and manufacturing requirements, while advances in aseptic filling and multi-dose preservative-free technologies are unlocking new commercial options.

Packaging and delivery innovation are equally consequential. Unit-dose formats are gaining traction where sterility and travel convenience are prioritized, while multi-dose containers continue to evolve across size bands to satisfy chronic use and cost sensitivity. The rise of online pharmacies, which includes brand-direct webstores and third-party e-retailers, is changing purchase behaviors and accelerating direct-to-consumer engagement. Retail pharmacy dynamics-where chain and independent outlets follow different stocking and promotional logics-are forcing manufacturers to introduce differentiated go-to-market tactics. Across applications, acoustics of demand have shifted; allergic conjunctivitis and post-surgical care require distinct clinical narratives compared with primary or secondary dry eye management. These structural shifts collectively demand that stakeholders reevaluate product roadmaps, channel investments, and evidence-generation plans to remain competitive.

Rigorous assessment of the cumulative impact of United States tariffs in 2025 on supply chains, sourcing strategies, pricing pressure, and manufacturer responses

The introduction of tariffs in the United States in 2025 has had a cumulative effect that ripples through procurement, manufacturing, and channel economics. Increased duties on certain imported active materials, specialty polymers used in multi-dose systems, and packaging components intensified cost pressures for manufacturers who rely on global supply chains. As a result, procurement teams accelerated dual-sourcing strategies and sought closer partnerships with regional suppliers to reduce exposure to further trade volatility. For inputs such as high molecular weight hyaluronic acid and specialized plastics for preservative-free delivery systems, the tariffs amplified incentives for upstream integration and long-term supply agreements.

These policy-induced cost dynamics also influenced product mix and channel tactics. Manufacturers with narrow margins reassessed the viability of certain lower-priced multi-dose SKUs and explored value engineering to maintain accessibility without degrading product performance. Distributors and retail partners recalibrated assortment strategies, with hospital pharmacies and chain retail outlets negotiating longer-term purchasing terms to stabilize supply. Online channels showed greater flexibility in absorbing incremental costs through tiered pricing or subscription models that smooth consumer spend. In parallel, some companies accelerated investments in domestic manufacturing and contract-filling capacity to sidestep duties, while regulatory teams intensified dialogue with authorities to ensure compliance and expedite approvals for relocated production. The net effect is a more complex commercial environment where supply chain resilience and sourcing strategy are as critical as formulation differentiation.

In-depth segmentation insights decoding product types, active ingredient preferences, distribution channels, application use cases, and volume formats influencing strategy

Segmentation offers a practical lens to translate clinical needs and commercial opportunity into concrete product and channel strategies. Product type segmentation spans drops, gels, ointments, and sprays, with further granularity for drops into emulsion, solution, and suspension formats; gels into hypotonic and isotonic versions; ointments as lanolin-based or petrolatum-based preparations; and sprays delivered as mist or solution spray. This granularity matters because each sub-type has distinct formulation challenges, preservation requirements, and patient preferences, and therefore different manufacturing and regulatory implications.

Active ingredient segmentation is equally influential. Options include carboxymethylcellulose, hyaluronic acid in high and low molecular weight configurations, preservative-free formulations, and preserved variants that deploy benzalkonium chloride, polyquaternium 1, or sodium chlorite. These ingredient decisions drive clinical positioning and influence shelf life, compatibility with packaging, and marketing claims. Distribution channel segmentation encompasses hospital pharmacy, online pharmacy-split between brand websites and e-retailers-retail pharmacy with chain and independent formats, and supermarkets or hypermarkets. Channel choice shapes promotional priorities, reimbursement pathways, and inventory management. Application type segmentation covers allergic conjunctivitis, dry eye syndrome including primary and secondary classifications, irritation relief across mild to severe gradations, and post-surgery care; each application implies different labeling, evidence needs, and clinician engagement strategies. Volume type segmentation differentiates multi-dose and unit-dose formats, with multi-dose broken into under 5 ml, 5 to 10 ml, and over 10 ml sizes, and unit-dose typically at 0.5 ml and 1 ml. These volume distinctions affect user convenience, regulatory categorization for sterility, and cost-to-manufacture calculations. Synthesizing these segmentation dimensions enables more precise targeting of R&D, regulatory dossiers, and commercial rollout plans.

Regional intelligence synthesizing demand drivers, regulatory landscapes, manufacturing footprints, and channel adoption trends across Americas, EMEA, and Asia-Pacific

Regional dynamics produce materially different commercial and operational imperatives. In the Americas, patient access, direct-to-consumer marketing, and strong online channel adoption coexist with a regulatory environment that emphasizes product safety and labeling clarity. Manufacturers serving the Americas often prioritize rapid fulfillment and omnichannel inventory strategies, and the region remains a prime target for differentiated preservative-free offerings and subscription models that support chronic use.

In Europe, the Middle East, and Africa, regulatory complexity and heterogeneous reimbursement systems necessitate tailored market entry strategies and careful compliance planning. European markets tend to emphasize clinical evidence and product quality claims, while certain Middle Eastern and African jurisdictions present opportunities for cost-sensitive multi-dose formats and regionally adapted packaging. In contrast, Asia-Pacific combines a dense manufacturing base with rapidly evolving clinical adoption. The region is notable for production capacity in active ingredients and primary packaging, which supports both global sourcing and localized manufacturing for tariff mitigation. Consumer behaviors also vary widely across the region; online pharmacies and brand websites are expanding quickly in some markets, while traditional retail remains dominant in others. Understanding these regional nuances is essential for aligning manufacturing locations, regulatory timelines, and channel investments with commercial outcomes.

Corporate insights into how established manufacturers, agile specialists, contract manufacturers, and new entrants are reshaping portfolios, partnerships, and commercialization approaches

Company behavior in the artificial tears space reflects strategic diversity: large incumbent manufacturers focus on scale, regulatory depth, and broad distribution networks, while specialist firms and newer entrants concentrate on niche differentiation such as preservative-free technologies or molecular-weight optimized hyaluronic acid. Contract manufacturers and contract development organizations are increasingly important partners, enabling faster scale-up for novel formulations and providing flexibility to respond to tariff-driven sourcing shifts.

Commercial strategies show a mix of consolidation and targeted partnerships. Established players are strengthening direct-to-consumer and professional relationships through co-marketing agreements and clinical evidence generation, while agile specialists invest in digital-first channels and sampling programs to accelerate trial. Packaging and device specialists are partnering with formulators to deliver multi-dose preservative-free solutions and user-friendly unit-dose systems. Across the ecosystem, companies are prioritizing quality systems, supply chain transparency, and traceability to meet regulatory scrutiny and clinician expectations. Successful firms also deploy differentiated evidence programs to substantiate claims for specific indications such as post-surgery care or severe dry eye, recognizing that robust clinical narratives materially affect uptake among prescribers and institutional buyers.

Actionable, prioritized recommendations for industry leaders to accelerate growth, mitigate tariff risks, optimize distribution, and enhance differentiation through innovation

Industry leaders should prioritize a set of practical actions that balance short-term resilience with long-term differentiation. First, diversify sourcing strategies for critical inputs and packaging to mitigate tariff exposure and supply interruptions, and evaluate nearshoring or regional manufacturing partnerships where regulatory and cost trade-offs are favorable. Second, accelerate investment in preservative-free delivery systems and in-depth clinical programs that validate high versus low molecular weight hyaluronic acid benefits, because clinical differentiation is increasingly central to professional and consumer choice.

Third, align commercial models with evolving channel dynamics by strengthening brand-direct channels and forming strategic partnerships with e-retail platforms while preserving relationships with hospital, chain, and independent pharmacies. Fourth, optimize packaging portfolios by balancing unit-dose convenience with the cost efficiencies of multi-dose systems across appropriate size bands, and assess reusable multi-dose technologies that meet sterility expectations. Fifth, invest in sustainability across packaging and supply chain operations to meet both regulatory scrutiny and consumer expectations. Finally, embed tariff-scenario planning into commercial and R&D roadmaps so that product launches, pricing strategies, and contractual commitments remain resilient under shifting trade policies. Prioritizing these steps will support both competitive differentiation and operational stability.

Transparent research methodology detailing data sources, expert consultations, product mapping, supply chain analysis, and validation techniques underpinning conclusions

The research approach combined systematic secondary analysis with targeted primary engagement and rigorous validation. Secondary inputs included peer-reviewed clinical literature, regulatory guidance and public filings, patent landscapes, supplier capability reports, and anonymized channel performance indicators. These sources were used to build a comprehensive mapping of product subtypes, ingredient pathways, volume formats, and distribution mechanics. Primary research comprised structured interviews with ophthalmologists, hospital pharmacists, formulators, packaging engineers, and commercial leaders across manufacturers and distributors to capture practical constraints and emergent strategies.

Data synthesis proceeded through triangulation methods to reconcile varying inputs and to surface consistent patterns across geographies and channel types. Supply chain mapping was used to identify concentrations of risk, particularly for high molecular weight hyaluronic acid and specialized packaging components. Scenario analysis was applied to evaluate the operational implications of tariff-related disruptions and to test the sensitivity of go-to-market models under differing channel mixes. Quality assurance steps included cross-validation of key findings with independent clinical and regulatory experts to ensure accuracy and to sharpen the implications for R&D, operations, and commercial teams. Limitations included variability in proprietary pricing and contract terms that remain confidential to firms, and where applicable, qualitative judgment was applied to interpret those signals.

Concise conclusion synthesizing strategic implications for stakeholders with emphasis on resilience, patient-centric product design, and operational prioritization

The artificial tears sector is at an inflection point where clinical expectations, packaging innovation, digital channels, and trade policy interact to reshape competitive dynamics. Stakeholders who integrate formulation science-especially around hyaluronic acid molecular variants and preservative-free technologies-with pragmatic supply chain strategies will be better positioned to respond to clinician preferences and patient convenience demands. Simultaneously, familiarity with channel nuances from hospital pharmacies through brand e-commerce is essential to translate product differentiation into sustainable adoption.

Operational resilience, particularly in sourcing and manufacturing footprint decisions, will be a defining capability given recent tariff-driven shifts. Companies that proactively align R&D, regulatory evidence generation, and distribution investments will capture disproportionate value by offering clinically substantiated, convenient, and accessible products. Ultimately, the ability to convert segmentation insight into focused portfolios, supported by flexible supply chains and channel-specific commercialization, will determine which organizations lead and which follow as the market evolves.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Tears Market, by Product Type

  • 8.1. Eye Drops
  • 8.2. Gels
  • 8.3. Ointments
  • 8.4. Sprays

9. Artificial Tears Market, by Active Ingredient

  • 9.1. Carboxymethylcellulose
  • 9.2. Hyaluronic Acid
  • 9.3. Polyethylene Glycol (PEG)
  • 9.4. Polyvinyl Alcohol

10. Artificial Tears Market, by Application

  • 10.1. Allergic Conjunctivitis
  • 10.2. Post Operative Support
  • 10.3. Dry Eye Syndrome

11. Artificial Tears Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Artificial Tears Market, by Age Group

  • 12.1. Adults
  • 12.2. Pediatrics

13. Artificial Tears Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Tears Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Tears Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Tears Market

17. China Artificial Tears Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alcon Inc.
  • 18.6. AbbVie Inc.
  • 18.7. Bausch + Lomb Corporation
  • 18.8. Abbott Laboratories
  • 18.9. Johnson & Johnson Services, Inc.
  • 18.10. Otsuka Pharmaceutical Co., Ltd.
  • 18.11. Santen Pharmaceutical Co., Ltd.
  • 18.12. Novartis AG
  • 18.13. Perrigo Company plc
  • 18.14. Pfizer Inc.
  • 18.15. Bayer AG
  • 18.16. Dr. Reddy's Laboratories Ltd.
  • 18.17. AFT Pharmaceuticals Limited
  • 18.18. Aldeyra Therapeutics, Inc.
  • 18.19. CooperVision, Inc.
  • 18.20. Eyenovia, Inc.
  • 18.21. Hilco Vision LLC
  • 18.22. I-MED Pharma Inc.
  • 18.23. Lupin Limited
  • 18.24. Menicon Co., Ltd.
  • 18.25. Nicox S.A.
  • 18.26. Ocular Therapeutix, Inc.
  • 18.27. Similasan Corporation
  • 18.28. Sun Pharmaceutical Industries Limited
  • 18.29. Thea Pharma, Inc.
  • 18.30. URSAPHARM Arzneimittel GmbH
  • 18.31. Velocity Pharma LLC
  • 18.32. Wuhan Yuanda Pharmaceutical Group Co., Ltd.
  • 18.33. Zhongshan Wanhan Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL TEARS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL TEARS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY CARBOXYMETHYLCELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY CARBOXYMETHYLCELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY CARBOXYMETHYLCELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYETHYLENE GLYCOL (PEG), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYETHYLENE GLYCOL (PEG), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYETHYLENE GLYCOL (PEG), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYVINYL ALCOHOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYVINYL ALCOHOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYVINYL ALCOHOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ALLERGIC CONJUNCTIVITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ALLERGIC CONJUNCTIVITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ALLERGIC CONJUNCTIVITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POST OPERATIVE SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POST OPERATIVE SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POST OPERATIVE SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DRY EYE SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DRY EYE SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 138. NATO ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)